| Description |
This immunotoxin was achieved by conjugating/fusing the Anti-ERBB2 monoclonal antibody to saporin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to ovarian cancer cells and enters cells by receptor-mediated endocytosis. Upon release of the conjugate from endosomes, the saporin toxin catalytically renders the large subunit ribosomes unable to bind the elongation factors and inhibits protein synthesis. It was designed for treatment of ovarian Cancer .
|